Israel Englander’s Arbutus Biopharma ABUS Stock Holding History

Israel Englander’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-150,000	Closed	-$644K	–	6697
2021 Q3	$644K	Buy	+150,000	New	+$500K	﹤0.01%	5109

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Israel Englander's ABUS Position: Q2 2026 in Review

Israel Englander sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 642,448 shares — an estimated $2.89M sold.

Israel Englander first reported a position in ABUS in Q1 2014 and held it in 42 quarters. The position peaked at $16.2M in Q2 2015. 175 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Israel Englander reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
Israel Englander sold 642,448 Arbutus Biopharma shares in Q2 2026, an estimated $2.89M.
Israel Englander first reported a position in Arbutus Biopharma in Q1 2014 and held it in 42 quarters.
Israel Englander's Arbutus Biopharma position peaked at $16.2M in Q2 2015.
175 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.